These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19047126)

  • 1. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
    Heath EI; Hillman DW; Vaishampayan U; Sheng S; Sarkar F; Harper F; Gaskins M; Pitot HC; Tan W; Ivy SP; Pili R; Carducci MA; Erlichman C; Liu G
    Clin Cancer Res; 2008 Dec; 14(23):7940-6. PubMed ID: 19047126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
    Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
    Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
    Alva A; Slovin S; Daignault S; Carducci M; Dipaola R; Pienta K; Agus D; Cooney K; Chen A; Smith DC; Hussain M
    Invest New Drugs; 2012 Apr; 30(2):749-57. PubMed ID: 21049281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
    Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
    Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
    Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
    JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
    Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
    Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
    Oh WK; Galsky MD; Stadler WM; Srinivas S; Chu F; Bubley G; Goddard J; Dunbar J; Ross RW
    Urology; 2011 Sep; 78(3):626-30. PubMed ID: 21762967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
    Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
    Flaig TW; Plets M; Hussain MHA; Agarwal N; Mitsiades N; Deshpande HA; Vaishampayan UN; Thompson IM
    JAMA Oncol; 2017 Nov; 3(11):e170231. PubMed ID: 28358937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
    Ramalingam SS; Egorin MJ; Ramanathan RK; Remick SC; Sikorski RP; Lagattuta TF; Chatta GS; Friedland DM; Stoller RG; Potter DM; Ivy SP; Belani CP
    Clin Cancer Res; 2008 Jun; 14(11):3456-61. PubMed ID: 18519777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.
    Chi KN; Beardsley E; Eigl BJ; Venner P; Hotte SJ; Winquist E; Ko YJ; Sridhar SS; Weber D; Saad F
    Ann Oncol; 2012 Jan; 23(1):53-58. PubMed ID: 21765178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
    Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
    Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
    Morant R; Bernhard J; Maibach R; Borner M; Fey MF; Thürlimann B; Jacky E; Trinkler F; Bauer J; Zulian G; Hanselmann S; Hürny C; Hering F
    Ann Oncol; 2000 Feb; 11(2):183-8. PubMed ID: 10761753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ishill N; Sweeney SM; Deluca JK; Schwartz L; Bacik J; Motzer RJ
    Invest New Drugs; 2006 Nov; 24(6):543-6. PubMed ID: 16832603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
    Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB
    Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
    Heath EI; Gaskins M; Pitot HC; Pili R; Tan W; Marschke R; Liu G; Hillman D; Sarkar F; Sheng S; Erlichman C; Ivy P
    Clin Prostate Cancer; 2005 Sep; 4(2):138-41. PubMed ID: 16197617
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.